Aurora Biosciences Corporation

San Diego, CA 92121

SBIR Award Summary

Total Number of Awards 9
Total Value of Awards $2.16MM
First Award Date 12/15/98
Most Recent Award Date 08/01/01

Key Personnel

Last Name Name Awards Contact
Stack Jeffrey H Stack 1
Whitney Michael A Whitney 2
Zlokarnik Gregor Zlokarnik 3
Xanthopoulos Kleanthis G Xanthopoulos 2
Hamman Brian D Hamman 1

9 Awards Won

Phase 2 SBIR

Agency: Department of Health & Human Services
Topic:
Budget: 08/01/01 - 12/31/02

A large number of pharmacologically-active compounds synthesized in the Discovery phase of pharmaceutical R&D are rejected either because of unsuitable pharmacokinetics, or because of interactions with existing therapeutic drugs. In many cases this is because the compounds are either substrates or inhibitors of one or more cytochrome P450 enzyme...

Phase 2 SBIR

Agency: Department of Health & Human Services
Topic:
Budget: 08/01/01 - 07/31/02

Aurora has developed a gene-tagging method which uses a highly sensitive beta-lactamase (bla) reporter system to rapidly a) screen for novel genes which respond to immune activators, and b) identify drug candidates which inhibit this immune activation. Phase I activities demonstrated feasibility by isolating immunoresponsive clones and using one...

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic:
Budget: 02/01/01 - 07/31/01

DESCRIPTION (Verbatim from Applicant's Abstract): We propose to design and develop an assay technology platform for viral proteases possessing cis cleavage activity. As viral cis proteases are frequently responsible for the initial cleavage of the viral polyprotein, they are attractive targets for antivir...

Phase 2 SBIR

Agency: Department of Health & Human Services
Topic:
Budget: 08/01/00 - 07/31/01

Aurora has developed a gene-tagging method which uses a highly sensitive beta-lactamase (bla) reporter system to rapidly a) screen for novel genes which respond to immune activators, and b) identify drug candidates which inhibit this immune activation. Phase I activities demonstrated feasibility by isolating immunoresponsive clones and using one...

Phase 2 SBIR

Agency: Department of Health & Human Services
Topic:
Budget: 08/01/00 - 07/31/01

A large number of pharmacologically-active compounds synthesized in the Discovery phase of pharmaceutical R&D are rejected either because of unsuitable pharmacokinetics, or because of interactions with existing therapeutic drugs. In many cases this is because the compounds are either substrates or inhibitors of one or more cytochrome P450 enzyme...

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic:
Budget: 02/01/00 - 01/31/01

Proteins that possess a membrane-translocating sequence (MTS) derived from the FGF signal sequence can be translocated into cells (Rojas et. al, 1998). The MTS is proposed here for use in developing high-throughput (HTS) and ultra high-throughput drug screening (UHTS) assays. Increasingly, assays used in HTS and UHTS are fluorescence-based due t...

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic:
Budget: 08/01/99 - 01/31/00

A large number of pharmacologically-active compounds synthesized in the Discovery phase of pharmaceutical R&D are rejected either because of unsuitable pharmacokinetics, or because of interactions with existing therapeutic drugs. In many cases this is because the compounds are either substrates or inhibitors of one or more cytochrome P450 enzyme...

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic: PAR-98-066
Budget: 03/01/99 - 02/29/00

Our goals are to develop novel methods which rapidly identify genes and lead pharmaceutical compounds in the area of breast cancer. We have developed a gene-tagging method which uses highly sensitive B-lactamase (bla) reporter system to rapidly 1) screen for novel genes with expression profiles responsive to the presence or absence of estradiol,...

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic:
Budget: 12/15/98 - 11/30/99

Our goals are to develop novel methods which rapidly identify genes in living cells and lead pharmaceutical compounds in the area of immunomodulation. We will develop a functional read-out for tagged genes that uses a highly sensitive beta-lactamase (bla) gene reporter system to rapidly 1) screen for n...